FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia                            
  
  
      
      
    
  
 
                          Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations.